source
- FDA approves Eli Lilly's oral SERD Inluriyo combo for second-line metastatic breast cancerThe FDA has given approval to a new combination therapy from Eli Lilly that includes its oral selective estrogen receptor degrader, Inluriyo, for patients with metastatic breast cancer who have pro…
- EU regulator backs Novo's hemophilia A preventive therapy and recommends seven additional drugsThe European Medicines Agency's human medicines committee issued a positive opinion on Novo's preventive treatment for hemophilia A, indicating it meets the agency's standards for further developme…